DYADIC INTERNATIONAL

Dyadic International’s CEO Mark Emalfarb to Present at BIO CEO & Investor Conference

07 Feb 2022 07:30:01 By Nasdaq GlobeNewswire

Dyadic Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process

20 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Dyadic Announces a NIIMBL Coronavirus Grant Under the White House’s American Rescue Plan

22 Dec 2021 08:12:47 By Nasdaq GlobeNewswire

Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform

17 Dec 2021 06:00:00 By Nasdaq GlobeNewswire

Dyadic Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

10 Nov 2021 15:00:00 By Nasdaq GlobeNewswire

Dyadic Appoints Chief Business Officer to Executive Leadership Team

09 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Dyadic to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

27 Oct 2021 15:30:00 By Nasdaq GlobeNewswire

Dyadic to Present at H.C. Wainwright 23rd Annual Global Investment Conference

10 Sep 2021 07:30:00 By Nasdaq GlobeNewswire

Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics

11 Aug 2021 07:35:40 By Nasdaq GlobeNewswire

Dyadic Announces Technology Transfer and Licensing Agreement With South Africa’s Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent

27 Jul 2021 07:20:00 By Nasdaq GlobeNewswire

Dyadic’s C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal

28 Jun 2021 07:30:00 By Nasdaq GlobeNewswire

Dyadic announces development of COVID-19 Vaccine in India

26 May 2021 07:30:01 By Nasdaq GlobeNewswire

Dyadic to Present at Upcoming Events

03 May 2021 07:30:00 By Nasdaq GlobeNewswire

Dyadic International Hosting a Fireside Chat on “The Potential of the Transformative Dyadic C1 Protein Technology in Helping Meet Global Health Challenges”

22 Apr 2021 07:30:01 By Nasdaq GlobeNewswire

UPDATE -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical Trial

29 Mar 2021 07:30:00 By Nasdaq GlobeNewswire

Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants

23 Mar 2021 08:00:01 By Nasdaq GlobeNewswire

Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants

22 Mar 2021 20:00:00 By Nasdaq GlobeNewswire

Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants

22 Mar 2021 07:30:00 By Nasdaq GlobeNewswire

Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100

18 Mar 2021 07:30:00 By Nasdaq GlobeNewswire

Dyadic Announces Scientific Achievements Reported During ZAPI Stakeholders Virtual Web Meeting

09 Mar 2021 07:30:00 By Nasdaq GlobeNewswire